TY  - JOUR
AU  - Schwalbe, Edward C
AU  - Lindsey, Janet C
AU  - Danilenko, Marina
AU  - Hill, Rebecca M
AU  - Crosier, Stephen
AU  - Ryan, Sarra L
AU  - Williamson, Daniel
AU  - Castle, Jemma
AU  - Hicks, Debbie
AU  - Kool, Marcel
AU  - Milde, Till
AU  - Korshunov, Andrey
AU  - Pfister, Stefan M
AU  - Bailey, Simon
AU  - Clifford, Steven C
TI  - Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study.
JO  - Neuro-Oncology
VL  - 27
IS  - 1
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2024-02020
SP  - 222–236
PY  - 2025
N1  - Volume 27, Issue 1, January 2025, Pages 222–236
AB  - MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients' MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogeneity within MYC(N)-amplified MB and determined its relevance for improved disease management.We characterized the clinical and molecular correlates of MYC- (MYC-MB; n = 64) and MYCN-amplified MBs (MYCN-MB; n = 95), drawn from >1600 diagnostic cases.Most MYC-MBs were molecular group 3 (46/58; 79
KW  - MYC amplification (Other)
KW  - MYCN amplification (Other)
KW  - medulloblastoma (Other)
KW  - survival (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39377358
DO  - DOI:10.1093/neuonc/noae178
UR  - https://inrepo02.dkfz.de/record/293955
ER  -